NAOV - NanoVibronix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9000
+0.0100 (+0.35%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close2.8900
Open2.8140
Bid2.1700 x 3000
Ask2.9900 x 900
Day's Range2.8140 - 2.9215
52 Week Range2.4000 - 4.9800
Volume4,304
Avg. Volume7,210
Market Cap11.933M
Beta (3Y Monthly)-0.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga

    NanoVibronix Announces Planned Launch Of CBD Patch, Cream

    Nanocap medical device company NanoVibronix (NASDAQ: NAOV ) announced it's developing cannabidiol patches and cream utilizing a proprietary and nanoparticle-based infusion process. CBD is one of the naturally ...

  • Zacks Small Cap Research

    NAOV: Several Major Milestones Expected This Year Including FDA Filings for OTC PainShield, UroShield

    NanoVibronix (NAOV) filed their 10-Q for Q1 2019 ending March 31st and released a corresponding business update. OTC approval, if and when achieved, would be a major milestone as it would allow for purchase and use of PainShield without the need for a doctor’s prescription – which has been a major impediment to sales to-date.

  • Zacks Small Cap Research

    NAOV: Foundation Built in 2018, Expected to Catalyze Growth Beginning Later This Year

    Each day they completed a Visual Analog Scale (indicating pain severity) and medication logs (reporting how much pain medication they took). In addition, while control saw a 1.5% decrease in breakthrough pain medication use (including opioids), PainShield patients used 46.4% less. The improvements in VAS scores as well as in the amount of pain medications used (both favoring PainShield) were statistically significant (charts below).

  • Zacks Small Cap Research

    NAOV: Zacks SCR Initiates Coverage of NanoVibronix

    Zacks SCR Senior Med-Tech analyst and Director of Research Brian Marckx, CFA has initiated coverage of NanoVibronix, Inc. with a $9.00/share price target. NanoVibronix, Inc. (NAOV), develops, manufactures and commercializes proprietary low intensity low frequency wearable ultrasound medical devices for the treatment of pain, reduction in bacterial colonization and biofilm disruption, and for wound healing. The relative safety of low intensity, low frequency ultrasound and compact size and simple operation of NAOV’s technology lend themselves to at-home use.